Articles tagged with: Revlimid
NewsFlash »
Eighth Canadian Province Approves Revlimid Funding – Revlimid (lenalidomide) in combination with dexamethasone (Decadron) is now funded and accessible in Manitoba, Canada for multiple myeloma patients who have been previously treated. Only two provinces, Nova Scotia and Prince Edward Island, deny access to myeloma patients who do not have private insurance. Myeloma Canada, an organization dedicated to supporting myeloma patients, will continue campaigning for universal coverage of Revlimid. For more information, please see the Myeloma Canada press release.
Astex And MMRC Begin Phase 2 Study Of AT7519 For Myeloma – Astex Therapeutics has launched a Phase 2 clinical trial, funded by the Multiple Myeloma Research Consortium (MMRC), of AT7519 for relapsed or refractory multiple myeloma patients. AT7519 is a cyclin-dependent kinase inhibitor that prevents the growth and spread of myeloma cells by interfering with cell division. Previous trials have shown it has significant anti-tumor effect. AT7519 will be tested alone and in combination with Velcade (bortezomib). For more information, see the MMRC press release.
IMF Will Hold Myeloma Patient And Family Seminar – The International Myeloma Foundation (IMF) will hold an educational program for multiple myeloma patients and their families on August 27 and August 28 in Universal City, CA. Doctors in the myeloma field will answer questions and cover topics such as managing side effects, current standard treatments, and on-going clinical trials. The cost for the seminar is $60 per person. For more information or to register, please see the IMF website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News»
A Phase 1 study found the four-drug combination of Revlimid-Velcade-dexamethasone-cyclophosphamide (RVCD) to be safe and effective in newly diagnosed, previously untreated multiple myeloma patients.
These results suggest that adding cyclophosphamide as the fourth drug in the treatment therapy may be just as or more effective than traditional two- and three-drug combinations. The study also determined that 500 mg/m2 cyclophosphamide, the highest dose tested, could safely be used in the RVCD drug combination.
Previous studies have shown that three-drug combinations can be very effective, including the Revlimid (lenalidomide)-Velcade (bortezomib)-dexamethasone …
News»
A statistical analysis of two Phase 3 trials found relapsed and refractory multiple myeloma patients who achieved complete remission and very good partial response to Revlimid and dexamethasone combination treatment had higher overall survival rates and longer times to disease progression compared to patients who only achieved partial response.
The analysis also showed that patients’ response to Revlimid and dexamethasone improved over time with continuous treatment.
The authors of the analysis therefore suggested continuing treatment in patients who achieved partial response as long as possible to achieve best outcome.
They added that …
NewsFlash »
Revlimid Granted Approval For Multiple Myeloma In Japan – Celgene announced last week that Revlimid (lenalidomide) has been approved for the treatment of relapsed and refractory multiple myeloma in combination with dexamethasone (Decadron) in Japan. Revlimid will be available through Revmate, a proprietary distribution program. For more information, please read the Celgene press release.
Immunomedics Doses First Multiple Myeloma Patient With Milatuzumab-Doxorubicin Combination – Immunomedics has dosed the first patient in a Phase 1/2 study of its milatuzumab-based treatment for multiple myeloma. This treatment has doxorubicin (Adriamycin), a chemotherapy drug, bound to milatuzumab, an antibody. It will be evaluated for its efficacy as a treatment for relapsed and refractory multiple myeloma patients. For more information, please see the Immunomedics press release and the clinical trial description.
ImmunoGen And Sanofi-Aventis Announce Beginning Of Phase 1 Trial Of Potential New Myeloma Treatment – ImmunoGen Inc. and Sanofi-Aventis announced the initiation of a Phase 1 clinical trial of SAR650984, an antibody that targets cancer cells. In preclinical testing, SAR650984 was found to have anti-cancer effects, and is now being investigated as a treatment for relapsed and refractory multiple myeloma as well as other blood cancers. For more information, please refer to the ImmunoGen press release.
News»
Preliminary results from a Phase 1 clinical trial suggest that everolimus (RAD001), in combination with Revlimid (lenalidomide), may have potential in the treatment of relapsed/refractory multiple myeloma. The findings were presented on June 4 at the American Society of Clinical Oncology (ASCO) annual meeting.
Everolimus is marketed by Novartis under the brand name Afinitor for the treatment of advanced kidney cancer and under the name Zortress to prevent kidney transplant rejection. Everolimus is currently being investigated as a potential treatment for multiple myeloma, and …
News»
Treatment of newly diagnosed multiple myeloma patients with a combination of cyclophosphamide (Cytoxan), Velcade (bortezomib), and dexamethasone (Decadron) (abbreviated CyBorD) appears to be effective and safe. The findings were presented June 5 in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.
The study compared CyBorD with Revlimid (lenalidomide)-dexamethasone treatment (abbreviated RD) and cyclophosphamide-Revlimid-dexamethasone treatment (abbreviated CRD). The results of the Phase 2 trials indicate that RD and CyBorD treatment were similar in efficacy and safety. CRD, however, was not as effective and had …
News, Resources»
This article describes a myeloma patient’s experience participating in a clinical trial. It is part of a series of articles intended to help clarify the clinical trial process.
In August 2008, Phil Brabbs was diagnosed with smoldering myeloma, which most physicians do not treat until symptoms begin and the disease progresses to multiple myeloma. After more than a year of physicians carefully reviewing his blood work, Phil’s smoldering myeloma progressed to multiple myeloma, and his physicians wanted to begin treatment.
Phil’s doctor suggested that he participate in a clinical trial that would …